ASKA Pharmaceutical Holdings Co.,Ltd. Share Price

Equities

4886

JP3119660003

Pharmaceuticals

Market Closed - Japan Exchange 07:00:00 26/04/2024 BST 5-day change 1st Jan Change
2,260 JPY +0.09% Intraday chart for ASKA Pharmaceutical Holdings Co.,Ltd. +2.40% +26.68%

Financials

Sales 2024 * 63.28B 405M 32.29B Sales 2025 * 64.65B 414M 32.99B Capitalization 64.02B 410M 32.67B
Net income 2024 * 6.47B 41.43M 3.3B Net income 2025 * 4.89B 31.36M 2.5B EV / Sales 2024 * 0.75 x
Net cash position 2024 * 16.35B 105M 8.34B Net cash position 2025 * 20.83B 133M 10.63B EV / Sales 2025 * 0.67 x
P/E ratio 2024 *
9.89 x
P/E ratio 2025 *
13.1 x
Employees 747
Yield 2024 *
1.77%
Yield 2025 *
2.12%
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Ha Tay Pharmaceutical JSC announced that it has received VND 180.6 billion in funding from ASKA Pharmaceutical Holdings Co.,Ltd. CI
ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021. CI
ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback announced on July 12, 2021, has closed with 300,000 shares, representing 1.06% for ¥316.48 million. CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021. CI
Tranche Update on ASKA Pharmaceutical Holdings Co.,Ltd.'s Equity Buyback Plan announced on July 12, 2021. CI
ASKA Pharmaceutical Holdings Co.,Ltd. announces an Equity Buyback for 300,000 shares, representing 1.05% for ¥350 million. CI
ASKA Pharmaceutical Holdings Co.,Ltd. authorizes a Buyback Plan. CI
ASKA Pharmaceutical Holdings Co., Ltd. acquired 20.04% stake in Japan Glass Industry Co., Ltd. CI
Ribomic Inc. and ASKA Pharmaceutical Co., Ltd. Announces Execution of A Multi-Year Joint Research and Development Agreement for Drug Discovery Research and Development CI
ASKA Pharmaceutical Co., Ltd. acquired additional 20% stake in Ha Tay Pharmaceutical JSC. CI
ASKA Pharmaceutical Co., Ltd. completed the acquisition of 24.9% stake in Ha Tay Pharmaceutical JSC. CI
Ha Tay Pharmaceutical JSC announced that it has received VND 369.70241 billion in funding from ASKA Pharmaceutical Co., Ltd. CI
Ha Tay Pharmaceutical JSC announced that it expects to receive VND 369.70241 billion in funding from ASKA Pharmaceutical Co., Ltd. and other investors CI
ASKA Pharmaceutical Co., Ltd. signed an agreement to acquire 24.9% stake in Ha Tay Pharmaceutical JSC. CI
More news
1 day+0.09%
1 week+2.40%
Current month+1.85%
1 month+2.26%
3 months+13.68%
6 months+32.16%
Current year+26.68%
More quotes
1 week
2 215.00
Extreme 2215
2 314.00
1 month
2 145.00
Extreme 2145
2 314.00
Current year
1 787.00
Extreme 1787
2 314.00
1 year
1 207.00
Extreme 1207
2 314.00
3 years
919.00
Extreme 919
2 314.00
5 years
776.00
Extreme 776
2 314.00
10 years
772.00
Extreme 772
2 314.00
More quotes
Managers TitleAgeSince
President 71 31/03/21
Chief Administrative Officer - -
Compliance Officer - 31/03/21
Members of the board TitleAgeSince
President 71 31/03/21
Director/Board Member 65 31/03/21
Director/Board Member 75 31/03/21
More insiders
Date Price Change Volume
26/04/24 2,260 +0.09% 45,100
25/04/24 2,258 -0.22% 52,100
24/04/24 2,263 +1.07% 38,400
23/04/24 2,239 +0.77% 28,800
22/04/24 2,222 +0.68% 22,100

Delayed Quote Japan Exchange, April 26, 2024 at 07:00 am

More quotes
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company mainly operates in two business segments. The Pharmaceutical segment is mainly engaged in the manufacture, purchase and sale of pharmaceutical products. The Others segment is involved in the manufacture of veterinary drugs, the provision of clinical testing services, the outsourcing of testing services, the purchase and sale of medical equipment, as well as the sale of health foods.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2,260 JPY
Average target price
2,667 JPY
Spread / Average Target
+17.99%
Consensus